Research appointment pre-doc
06/MEDS-02 - Experimental Medicine, Pathophysiology And Clinical Pathology
Uni. Brescia
Posted on: 16/11/2026 Deadline: 01/12/2026

Blocking the FGF/FGFR system as a new therapeutic strategy for c-Myc-driven aggressive B-cell non-Hodgkin lymphoma

B-cell non-Hodgkin lymphomas (B-NHL), including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), are aggressive malignancies frequently driven by c-MYC. Despite current therapies, relapse remains common, highlighting the need for novel strategies. Our data indicate that FGF/FGFR signaling stabilizes c-MYC and that its inhibition induces c-MYC proteasomal degradation. We hypothesize that FGF/FGFR blockade may impair c-MYC-driven B-NHL growth and dissemination. Using FGF trapping and FGFR inhibitors, we will investigate the biological and molecular effects of FGF/FGFR blockade in DLBCL and BL in vitro and in vivo, assess its therapeutic efficacy alone or combined with R-CHOP, and develop novel FGF-trap molecules. This study may establish FGF/FGFR signaling as a novel therapeutic vulnerability inaggressive c-MYC-driven B-NHL

Selection process

Public notice for the direct approval of a research position pursuant to Article 22-ter, paragraph 4, of Law No. 240/2010, a.d. MEDS-02/A “Experimental Medicine and Pathophysiology" The evaluation criteria are established in the call; a master's degree obtained no more than six years ago is required; knowledge of Italian and English is required.The preferred professional competence for the collaboration to be established will concern experience in: cellular biology, molecular biology, lymphoma biology, study of the tumor microenvironment, study of angiogenesis processes, study of intracellular molecular pathways, and in vivo models of experimental oncology.
Back to jobs